BioMarin Pharmaceutical BMRN
United StatesHealthcare · BiotechnologyUSD
91.62 USD (+66.0%)
26 analysts
Trading 2120.30 €Open account ↗
Lightyear0.90 €Open account ↗
N260.90 €Open account ↗
XTB1.00 €★ featured · affiliateOpen account ↗Trading 2120.30 €Open account ↗Lightyear0.90 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗200.00 € order · cheapest cheapest available in your country iCompare all 22 brokers →What does it do?
BioMarin Pharmaceutical is a biopharmaceutical company that develops and commercializes innovative therapies for rare genetic diseases, generating revenue from the sale of these specialized medicines.
Key points
from its scores- ✓Favourable backdrop8.6
- ✕Little or no dividend1.5
- ✕Little competitive advantage3.6
- ✕Demanding valuation4.1
AI analysis
bottom line, main risk, context and newsThe company has a product with potential, but the high leverage and weak current profitability justify waiting for the earnings recovery to materialize before taking a position.
BioMarin shows revenue growth of 19.90%, but its financial health is highly strained by a Net Debt/EBITDA of 5.16 and its profitability is weak (ROE 1.18%). Valuation is extremely demanding (P/E 149.19), although the forward P/E of 8.34 suggests the market expects a strong earnings recovery.
The main risk is the high financial leverage (Net Debt/EBITDA of 5.16), which in a rising interest rate environment could strain cash generation and limit the ability to invest in its pipeline.
Context and risks
BioMarin operates in the US biotechnology sector, subject to regulatory and drug pricing scrutiny that could impact its margin. Its high leverage (Net Debt/EBITDA of 5.16) amplifies exposure to a rising interest rate environment, increasing the cost of its debt and pressuring its long-term valuation.
Is BioMarin Pharmaceutical stock cheap or expensive?
at the analysis dateOn P/E and EV / EBITDA, it trades 254% above the Healthcare median on average.
| Multiple | Company | Sector | Difference |
|---|---|---|---|
| P/E | 149.2 | 26.7 | +458% |
| EV / EBITDA | 21.7 | 14.5 | +50% |
| Price / book | 1.7 | 4.1 | −59% |
| Price / sales | 3.1 | 3.4 | −8% |
Sector: median of the 217 Healthcare companies analysed. In bold, the multiples used for the comparison.
Valuation score: 4.1 out of 10 (median for Healthcare: 4.7).
Average analyst target: 91.62 USD, +66.0% versus the price.
A premium can be justified if the company is of higher quality or grows faster than its sector: Quality / Moat 3.6 (sector 5.5), Growth 4.1 (sector 6.6).
Classic formulas with standard assumptions (10.0% growth, 8-9% discount rate). Indicative only: they change a lot with the assumptions and are not a recommendation.
Work out its fair value yourself →How much would you have made investing every month? →
Comparing it with its sector does not say whether it is a good buy: this is not investment advice.
Score by category
0 to 10 · hover overtap each one to see what it measuresKey metrics
at the analysis date · compared with the Healthcare medianValuation
- P/E
- 149.2
- Forward P/E
- 8.3
- EV / EBITDA
- 21.7
- Price / book
- 1.7
- Price / sales
- 3.1
- PEG
- 0.33
- Market cap
- 10.7B USD
- Enterprise value
- 14.0B USD
Profitability
- ROE
- 1.2%
- ROA
- 3.3%
- ROIC (approx.)
- 6.8%
- Gross margin
- 51.0%
- Operating margin
- 21.2%
- Net margin
- 2.1%
- Free cash flow
- 85.2M USD
- FCF yield
- 0.8%
- Cash conversion
- 13%
Solvency
- Total debt
- 4.2B USD
- Net debt
- 3.3B USD
- Cash
- 874.0M USD
- EBITDA
- 645.3M USD
- Net debt / EBITDA
- 5.16
- Debt / equity
- 66.47
- Current ratio
- 2.39
- Quick ratio
- 1.16
Growth
- Revenue growth
- +19.9%
- Earnings growth
- −81.3%
- EPS (TTM)
- 0.37 USD
- EPS (forward)
- 6.62 USD
Dividend
- Dividend yield
- 0.0%
- Payout
- 0.0%
Risk and market
- Beta
- 0.21
- Analyst consensus
- Buy (26)
- Target price
- 91.62 USD
- 52-week range
- 49.26 – 70.98
Recent news
All BMRN news →Compare it with its sector
All 217 in Healthcare →Frequently asked questions about BioMarin Pharmaceutical
Is BioMarin Pharmaceutical stock cheap or expensive?
On P/E and EV / EBITDA, it trades 254% above the Healthcare median on average. Valuation score: 4.1 out of 10 (median for Healthcare: 4.7). Average analyst target: 91.62 USD, +66.0% versus the price. This is not investment advice.
What score does BioMarin Pharmaceutical get on MeridIAn Screener?
It scores 4.7 out of 10, rank 1,805 of 2,130 (better than 14% of the companies analysed). Its strongest category is Risk & Context (8.6) and its weakest, Dividend (1.5). Analysis of 08/10/2026.
What is BioMarin Pharmaceutical's P/E ratio?
Its P/E is 149.2: the share price equals 149.2 times earnings per share over the last 12 months. The Healthcare median is 26.7. Based on the earnings analysts expect, the forward P/E is 8.3.
How much is BioMarin Pharmaceutical worth on the stock market?
Its market capitalisation is 10.7B USD and its enterprise value, debt included, is 14.0B USD.
How much debt does BioMarin Pharmaceutical have?
Its net debt (debt minus cash) is 3.3B USD. That is 5.16 times its EBITDA; the Healthcare median is 1.53.
Does BioMarin Pharmaceutical pay a dividend?
It pays no dividend, or almost none.
How has BioMarin Pharmaceutical stock performed over the last year?
It has risen 5.5% over the last year, excluding dividends. Over the last 52 weeks it has traded between 49.26 and 70.98 USD. Past performance does not guarantee future results.
What do analysts think of BioMarin Pharmaceutical?
26 analysts cover it; their average recommendation is “Buy” and their average target is 91.62 USD (+66.0% versus the price). It is an estimate, not market data.